Novel phenyl nitrogen mustard and half-mustard derivatives of amidino-modified distamycin

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 23, 1997, Pages 2979-2984

  Cozzi, Paolo ^a   Beria, Italo ^a   Biasoli, Giovanni ^a   Caldarelli, Marina ^a   Capolongo, Laura ^a   Geroni, Cristina ^a   Mongelli, Nicola ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISTAMYCIN A; DISTAMYCIN A DERIVATIVE; TALLIMUSTINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOSE RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PKA; STRUCTURE ACTIVITY RELATION;

EID: 0030708710     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10120-2     Document Type: Article

References (20)

1. Pezzoni, G.; Grandi, M.; Biasoli, G.; Capolongo, L.; Ballinari, D.; Giuliani, F.C.; Barbieri, B.; Pastori, A.; Pesenti, E.; Mongelli, N.; Spreafico, F. Br. J. Cancer, 1991, 64, 1047.
2. Broggini, M.; Coley, H.M.; Mongelli, N.; Pesenti, E.; Wyatt, M.D.; Hartley, J.A.; D' Incalci, M. Nucleic Acid Research, 1995, 23, 81.
3. See e.g. a) Dwyer, T.J. ; Geierstanger, B.H. ; Bathini, Y. ; Lown, J.W. ; Wemmer, D.E. J. Am. Chem. Soc. 1992, 114, 5911 ;
4. b) Xie, G. ; Gupta, R. ; Lown, J.W. Anticancer Drug Design, 1995, 10, 389 ;
5. c) and for a review : Pindur, U. ; Fischer, G. Current Med. Chem. 1996, 3, 379.
6. See e.g. Zunino, F.; Animati, F.; Capranico, G. Current Pharmaceutical Design, 1995, 1, 83, and references therein.
7. See e.g. a) Lee, M. ; Rhodes, A.L. ; Wyatt, M. ; Forrow, S. ; Hartley, J. A. Anticancer Drug Design, 1993, 8, 173 ;
8. b) Wyatt, M.D. ; Garbiras, B.J. ; Haskell, M.K. ; Lee, M. ; Souhami, R.L. ; Hartley, J.A. Anticancer Drug Design, 1994, 9, 511 ;
9. c) Wyatt, M.D. ; Lee, M. ; Hartley, J.A. Anticancer Drug Design, 1997, 12, 49.
10. Previous paper in this issue
11. 6 ) are given. ( Bruker AC 200 spectrometer, δ in ppm, TMS as internal standard ). 1b: 8.82 (s, 1H); 7.87 (t, J=5.7Hz, 1H); 5.4 (b.s., 2H); 3.32 (m, 2H); 2.20 (m, 2H). 1c: 8.7 (b.s., 2H); 8.19 (t, J=5.7Hz, 1H); 5.0 (b.s., 2H); 3.44 (m, 2H); 2.57 (t, J=6.5Hz, 2H). 1d: 8.0 (b.s., 1H); 8.1 (b.s., 1H); 8.84 (m, 1H); 3.48 (q, J=6.7Hz, 2H); 2.61 (m, 2H). 1e: 9.55 (b.s., 1H); 9.1 (b.s., 1H); 8.6 (b.s., 1H), 8.26 (t, J=5.8Hz, 1H), 3.50 (m, 2H); 2.79 (s, 3H), 2.57 (m, 2H). 1g: 10.0 (b.s., 2H); 8.29(t, J=5.7Hz, 1H); 3.6-3.9 (m 4H); 3.48 (m, 2H); 2.68 (t, J=6.7Hz, 2H). 1h: 11.80 (b.s., 1H); 8.12 (t, J=5.8Hz, 1H); 6.87 (s, 2H); 3.42 (m, 2H); 2.81 (m, 2H). 1i: 8.12 (b.s., 1H); 7.65 (b.s., 1H); 7.2 (b.s., 4H); 3.1-3.4 (m, 4H). 1j: 8.12 (t, J=5.8Hz, 1H), 4.09 (t, 2H); 2.90 (t, 2H); 2.65 (s, 6H); 1.98 (m, 2H). 1k: 7.96 (t, J=5.9Hz, 1H); 7.34 (b.s., 2H); 3.33 (m, 2H); 2.30 (t, J=7.2Hz, 2H). 1l: 8.34 (t, J=6.0Hz, 1H); 3.40 (m, 2H); 2.72 (t, J=6.4Hz, 2H).1m: 8.08 (t, J=5.8Hz, 1H); 3.30 (m, 8H).
12. See e.g. :a) Gautier J. A.; Miocque, M.; Combet Farnoux, C. in The chemistry of amidine and imidates S. Patai Ed., John Wiley & Sons, N.Y. 1975, pp 283-348 ;
13. b) Watson, K. M.; Neilson, D. G. ibidem, pp 491-545 ;
14. c) Neilson, D.G. ibidem, pp 385-489.
15. Baker, P.L.; Gendler, P.L.; Rapoport, H. J.Org.Chem.1981, 46, 2456.
16. Bialer, M.; Yagen, B.; Mechoulam, R. Tetrahedron, 1978, 34, 2389.
17. Nishiwaki, E.; Tanaka, S.; Lee, H.; Shibuya, M. Heterocycles, 1988, 27, 1945.
18. Geroni, C.; Pesenti, E.; Tagliabue, G.; Ballinari, D.; Mongelli, N.; Broggini, M.; Erba, E.; D'Incalci, M. Cancer Res., 1993, 53, 308.
19. Marchini, S.; Cozzi, P.; Beria, I.; Geroni, C.; Capolongo, L.; D'Incalci, M.; Broggini, M.; submitted for publication to AnticancerDrug Design.
20. See e.g. Lown, J. W. Chemtracts-Organic Chemistry, 1993, 6, 205.